20.11.2014 - 21.11.2014
The complexity of their molecular structure, their targeted pharmacology and their difficult-to-predict clinical profiles, make monoclonal antibodies (mAbs) a promising but also challenging class of biological compounds. New mAbs face a highly competitive environment and only a few candidates will finally get an approval and market access. In most cases the high failure rate of mAb projects is attributable to a lack of efficacy, which often only becomes apparent during a suitable pivotal study. This seminar will guide you through these transitional phases of innovator mAb development. In addition, a highly topical subject will also be addressed: biosimilar mAbs.
Kontakt: Laura Eberhardt, FORUM Institut für Management GmbH